Cargando…

Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China

The novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global pandemic of the coronavirus disease 2019 (COVID-19), which elicits a wide variety of symptoms, ranging from mild to severe, with the potential to lead to death. Although used as the standard meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Xia, Yin, Jiming, Zhang, Jiaying, Hu, Yaling, Ouyang, Yabo, Qiao, Shubin, Zhao, Hong, Zhang, Tong, Li, Xuemei, Zhang, Lili, Zhang, Jie, Jin, Ronghua, Feng, Yingmei, Su, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005580/
https://www.ncbi.nlm.nih.gov/pubmed/33790892
http://dx.doi.org/10.3389/fimmu.2021.614436
_version_ 1783672138523213824
author Feng, Xia
Yin, Jiming
Zhang, Jiaying
Hu, Yaling
Ouyang, Yabo
Qiao, Shubin
Zhao, Hong
Zhang, Tong
Li, Xuemei
Zhang, Lili
Zhang, Jie
Jin, Ronghua
Feng, Yingmei
Su, Bin
author_facet Feng, Xia
Yin, Jiming
Zhang, Jiaying
Hu, Yaling
Ouyang, Yabo
Qiao, Shubin
Zhao, Hong
Zhang, Tong
Li, Xuemei
Zhang, Lili
Zhang, Jie
Jin, Ronghua
Feng, Yingmei
Su, Bin
author_sort Feng, Xia
collection PubMed
description The novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global pandemic of the coronavirus disease 2019 (COVID-19), which elicits a wide variety of symptoms, ranging from mild to severe, with the potential to lead to death. Although used as the standard method to screen patients for SARS-CoV-2 infection, real-time PCR has challenges in dealing with asymptomatic patients and those with an undetectable viral load. Serological tests are therefore considered potent diagnostic tools to complement real-time PCR-based diagnosis and are used for surveillance of seroprevalence in populations. However, the dynamics of the antibody response against SARS-CoV-2 currently remain to be investigated. Here, through analysis of plasma samples from 84 patients with COVID-19, we observed that the response of virus-specific antibodies against three important antigens, RBD, N and S, dynamically changed over time and reached a peak 5–8 weeks after the onset of symptoms. The antibody responses were irrespective of sex. Severe cases were found to have higher levels of antibody response, larger numbers of inflammatory cells and C-reactive protein levels. Within the mild/moderate cases, pairwise comparison indicated moderate association between anti-RBD vs. anti-N, anti-RBD vs. anti-S1S2, and anti-N vs. anti-S1S2. Furthermore, the majority of cases could achieve IgM and IgG seroconversion at 2 weeks since the disease onset. Analysis of neutralizing antibodies indicated that these responses were able to last for more than 112 days but decline significantly after the peak. In summary, our findings demonstrate the longitudinally dynamic changes in antibody responses against SARS-CoV-2, which can contribute to the knowledge of humoral immune response after SARS-CoV-2 infection and are informative for future development of vaccine and antibody-based therapies.
format Online
Article
Text
id pubmed-8005580
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80055802021-03-30 Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China Feng, Xia Yin, Jiming Zhang, Jiaying Hu, Yaling Ouyang, Yabo Qiao, Shubin Zhao, Hong Zhang, Tong Li, Xuemei Zhang, Lili Zhang, Jie Jin, Ronghua Feng, Yingmei Su, Bin Front Immunol Immunology The novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global pandemic of the coronavirus disease 2019 (COVID-19), which elicits a wide variety of symptoms, ranging from mild to severe, with the potential to lead to death. Although used as the standard method to screen patients for SARS-CoV-2 infection, real-time PCR has challenges in dealing with asymptomatic patients and those with an undetectable viral load. Serological tests are therefore considered potent diagnostic tools to complement real-time PCR-based diagnosis and are used for surveillance of seroprevalence in populations. However, the dynamics of the antibody response against SARS-CoV-2 currently remain to be investigated. Here, through analysis of plasma samples from 84 patients with COVID-19, we observed that the response of virus-specific antibodies against three important antigens, RBD, N and S, dynamically changed over time and reached a peak 5–8 weeks after the onset of symptoms. The antibody responses were irrespective of sex. Severe cases were found to have higher levels of antibody response, larger numbers of inflammatory cells and C-reactive protein levels. Within the mild/moderate cases, pairwise comparison indicated moderate association between anti-RBD vs. anti-N, anti-RBD vs. anti-S1S2, and anti-N vs. anti-S1S2. Furthermore, the majority of cases could achieve IgM and IgG seroconversion at 2 weeks since the disease onset. Analysis of neutralizing antibodies indicated that these responses were able to last for more than 112 days but decline significantly after the peak. In summary, our findings demonstrate the longitudinally dynamic changes in antibody responses against SARS-CoV-2, which can contribute to the knowledge of humoral immune response after SARS-CoV-2 infection and are informative for future development of vaccine and antibody-based therapies. Frontiers Media S.A. 2021-03-15 /pmc/articles/PMC8005580/ /pubmed/33790892 http://dx.doi.org/10.3389/fimmu.2021.614436 Text en Copyright © 2021 Feng, Yin, Zhang, Hu, Ouyang, Qiao, Zhao, Zhang, Li, Zhang, Zhang, Jin, Feng and Su. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Feng, Xia
Yin, Jiming
Zhang, Jiaying
Hu, Yaling
Ouyang, Yabo
Qiao, Shubin
Zhao, Hong
Zhang, Tong
Li, Xuemei
Zhang, Lili
Zhang, Jie
Jin, Ronghua
Feng, Yingmei
Su, Bin
Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China
title Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China
title_full Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China
title_fullStr Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China
title_full_unstemmed Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China
title_short Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China
title_sort longitudinal profiling of antibody response in patients with covid-19 in a tertiary care hospital in beijing, china
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005580/
https://www.ncbi.nlm.nih.gov/pubmed/33790892
http://dx.doi.org/10.3389/fimmu.2021.614436
work_keys_str_mv AT fengxia longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT yinjiming longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT zhangjiaying longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT huyaling longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT ouyangyabo longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT qiaoshubin longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT zhaohong longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT zhangtong longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT lixuemei longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT zhanglili longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT zhangjie longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT jinronghua longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT fengyingmei longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina
AT subin longitudinalprofilingofantibodyresponseinpatientswithcovid19inatertiarycarehospitalinbeijingchina